{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:42:37Z","timestamp":1783690957911,"version":"3.55.0"},"reference-count":69,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of off-label use of bevacizumab for neovascular ocular diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A PubMed (1966\u2013January 2007) search was conducted using the terms human, intravitreal, bevacizumab, macular, and retinopathy. Meeting abstracts from the American Academy of Ophthalmology, Retina Society, Macula Society, and Association for Research in Vision and Ophthalmology were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Controlled studies, unpublished reports involving 100 or more subjects, and published reports describing 5 or more subjects were reviewed. Only English-language articles were considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Intravitreal bevacizumab has been evaluated in 133 patients in unpublished controlled studies. Over 3500 patients have been evaluated in open-label studies with duration of follow-up ranging from 3 months to 1 year. The most common use was neovascular age-related macular degeneration (AMD). Other conditions studied included diabetic retinopathy, pathological myopia, neovascular glaucoma, and macular edema due to diabetes, retinal vein occlusion, or uveitis. Statistically significant improvements in visual acuity, as well as decreases in retinal thickness and the extent of choroidal neovascularization, were noted. Intravitreal bevacizumab was well tolerated over the short term. In a registry compiling adverse experiences of 7113 intravitreal injections, rates of adverse events were less than or equal to 0.21%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Uncontrolled studies support a benefit of intravitreal bevacizumab in neovascular AMD for 3 months to 1 year. Low cost is a significant advantage of bevacizumab. Patients should discuss the potential risks and benefits of intravitreal bevacizumab and other available therapies with their physicians before receiving treatment. Controlled trials are needed to characterize the safely and efficacy of intravitreal bevacizumab and determine the optimal treatment regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1h316","type":"journal-article","created":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T20:21:23Z","timestamp":1173817283000},"page":"614-625","source":"Crossref","is-referenced-by-count":126,"title":["Bevacizumab for Neovascular Ocular Diseases"],"prefix":"10.1177","volume":"41","author":[{"given":"Shalini S","family":"Lynch","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2007,4,1]]},"reference":[{"key":"bibr1-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.477"},{"key":"bibr2-aph.1H316","volume-title":"Age-related macular degeneration: what you should know. NIH publication no. 03-2294","year":"2003"},{"key":"bibr3-aph.1H316","unstructured":"VEGF inhibitors and \u201cwet\u201d macular degeneration. American Macular Degeneration Foundation. www.macular.org\/news\/aarpvegf.html (accessed 2006 Apr 21)."},{"key":"bibr4-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(05)80078-X"},{"key":"bibr5-aph.1H316","volume-title":"Package insert. Avastin (bevacizumab)","year":"2006"},{"key":"bibr6-aph.1H316","volume-title":"Package insert. Lucentis (ranibizumab injection)","year":"2006"},{"key":"bibr7-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381"},{"key":"bibr8-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1999.3192"},{"key":"bibr9-aph.1H316","unstructured":"Treatments for macular degeneration. AMD Alliance International. www.amdalliance.org\/amd-info\/personal\/treatments\/treatments.asp (accessed 2006 Mar 11)."},{"key":"bibr10-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.02.007"},{"key":"bibr11-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.070"},{"key":"bibr12-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000244380.34082.67"},{"key":"bibr13-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0471-7"},{"key":"bibr14-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0466-4"},{"key":"bibr15-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000246884.76018.63"},{"key":"bibr16-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000247165.38655.bf"},{"key":"bibr17-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000225766.75009.3a"},{"key":"bibr18-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200604000-00001"},{"key":"bibr19-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"bibr20-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200603000-00005"},{"key":"bibr21-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.02.037"},{"key":"bibr22-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.02.015"},{"key":"bibr23-aph.1H316","author":"Abraham-Marin ML","year":"2006","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"bibr24-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0412-5"},{"key":"bibr25-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000247164.70376.91"},{"key":"bibr26-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.099887"},{"key":"bibr27-aph.1H316","doi-asserted-by":"publisher","DOI":"10.3928\/15428877-20061101-01"},{"key":"bibr28-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.064"},{"key":"bibr29-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.06.066"},{"key":"bibr30-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0512-2"},{"key":"bibr31-aph.1H316","volume-title":"Package insert. Macugen (pegaptanib sodium injection)","year":"2006"},{"key":"bibr32-aph.1H316","author":"Spaide RF","year":"2006","journal-title":"Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting"},{"key":"bibr33-aph.1H316","author":"Brooks HL","year":"2006","journal-title":"Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting"},{"key":"bibr34-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200603000-00003"},{"key":"bibr35-aph.1H316","author":"Eichenbaum DA","year":"2006","journal-title":"Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting"},{"key":"bibr36-aph.1H316","author":"Wu L","year":"2006","journal-title":"Presented at: 2006 American Academy of Ophthalmology\/Asia Pacific Academy of Ophthalmology Joint Meeting"},{"key":"bibr37-aph.1H316","author":"Eliwa TF","year":"2006","journal-title":"Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting"},{"key":"bibr38-aph.1H316","author":"Thomas EL","year":"2006","journal-title":"Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting"},{"key":"bibr39-aph.1H316","author":"Lalin SC","year":"2006","journal-title":"Presented at: 2006 American Academy of Ophthalmology\/Asia Pacific Academy of Ophthalmology Joint Meeting"},{"key":"bibr40-aph.1H316","author":"Pelayes DE","year":"2006","journal-title":"Presented at: 2006 American Academy of Ophthalmology\/Asia Pacific Academy of Ophthalmology Joint Meeting"},{"key":"bibr41-aph.1H316","author":"Avery RL","year":"2006","journal-title":"Presented at: 2006 American Academy of Ophthalmology\/Asia Pacific Academy of Ophthalmology Joint Meeting"},{"key":"bibr42-aph.1H316","author":"Esfahani MR","year":"2006","journal-title":"Presented at: 2006 American Academy of Ophthalmology\/Asia Pacific Academy of Ophthalmology Joint Meeting"},{"key":"bibr43-aph.1H316","author":"Ahmadieh J","year":"2006","journal-title":"Presented at: 2006 American Academy of Ophthalmology\/Asia Pacific Academy of Ophthalmology Joint Meeting"},{"key":"bibr44-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000234629.22614.cd"},{"key":"bibr45-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0433"},{"key":"bibr46-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00819.x"},{"key":"bibr47-aph.1H316","author":"Chan CK","year":"2006","journal-title":"Presented at: 2006 American Academy of Ophthalmology\/Asia Pacific Academy of Ophthalmology Joint Meeting"},{"key":"bibr48-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.06.048"},{"key":"bibr49-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.093732"},{"key":"bibr50-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.07.037"},{"key":"bibr51-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00765.x"},{"key":"bibr52-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1177\/112067210601600521"},{"key":"bibr53-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.108795"},{"key":"bibr54-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.08.003"},{"key":"bibr55-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.099598"},{"key":"bibr56-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-006-1352-5"},{"key":"bibr57-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200410001-00002"},{"key":"bibr58-aph.1H316","unstructured":"Statement on Avastin. Position statement released by AMD Alliance International. www.amdalliance.org\/information\/treatments\/treatments.php (accessed 2006 Sept 20)."},{"key":"bibr59-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.082255"},{"key":"bibr60-aph.1H316","volume-title":"Risk management recommendations for off-label, intravitreal use of Avastin"},{"key":"bibr61-aph.1H316","first-page":"1462","volume":"50","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"bibr62-aph.1H316","unstructured":"Trissel L. An update on USP chapter 797: the new national standard for sterile preparation. www.ashpadvantage.com\/website_images\/pdf\/hospira797.pdf (accessed 2006 Mar 6)."},{"key":"bibr63-aph.1H316","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000225354.92444.7a"},{"key":"bibr64-aph.1H316","author":"Guerrero-Naranjo J","year":"2006","journal-title":"Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting"},{"key":"bibr65-aph.1H316","first-page":"21","volume":"25","year":"2006","journal-title":"Thomson Health Care Redbook Update"},{"key":"bibr66-aph.1H316","first-page":"42","volume":"24","year":"2005","journal-title":"Thomson Health Care Redbook Update"},{"key":"bibr67-aph.1H316","unstructured":"Witkowski W Troise DJ. Genentech shares rise on FDA approval of Lucentis age-related blindness treatment. http:\/\/biz.yahoo.com\/ap\/060630\/genentech_novartis.html (accessed 2006 Aug 6)."},{"key":"bibr68-aph.1H316","unstructured":"www.clinicaltrials.gov (accessed 2006 Sept 20)."},{"key":"bibr69-aph.1H316","unstructured":"National Institutes of Health stimulates the development and testing of new therapies for advanced age-related macular degeneration (AMD). National Eye Institute Statement. http:\/\/www.nei.nih.gov\/news\/statements\/amd_therapy.asp (accessed 2006 December 13)."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1H316","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1H316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:59Z","timestamp":1777374539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1H316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1345\/aph.1H316"],"URL":"https:\/\/doi.org\/10.1345\/aph.1h316","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}